Deleted Journal, Год журнала: 2023, Номер 71(5), С. 388 - 391
Опубликована: Май 1, 2023
Dermatology and Therapy, Год журнала: 2024, Номер 14(4), С. 919 - 932
Опубликована: Март 21, 2024
Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval patients with AD after being evaluated in several clinical trials. However, a few concerns raised regarding their long-term safety management these drugs real-world practice. this article we described results Delphi consensus aimed at describing knowledge on JAKi focusing, providing recommendations dermatologists daily practice use drugs. Twelve Italian reviewed most recent literature efficacy profiles proposed 24 statements. Agreement was reached statements focusing three main topics: (1) place therapy moderate-to-severe AD; (2) effectiveness JAK different phenotypes; (3) approaches to treated The panel all Given wide practice, it is crucial establish specific follow-up each patient's phenotype order achieve best possible outcome minimize potential adverse events.
Язык: Английский
Процитировано
18
Life, Год журнала: 2023, Номер 13(6), С. 1419 - 1419
Опубликована: Июнь 20, 2023
The latest findings regarding AD pathogenesis point to an impaired function of the epidermal barrier, changed immune response, colonization skin by microorganisms, and certain psychological factors among other causes/triggers. inflammatory response patients is mainly associated with activation T cells (Th2 predominate), dendritic cells, macrophages, keratinocytes, mast eosinophils. Therapy usually involves medical evaluations adequate management including treatment concomitant diseases (e.g., allergies infections), patient education nursing care, support, nutritional consultations, which are organized through specific programs structured educational groups. Systemic therapy includes conventional systemic (cyclosporine, methotrexate, azathioprine) new, drugs, interleukin inhibitors dupilumab) JAK (baricitinib, abrocitinib, upadacitinib, etc.). Since many affected various comorbidities, they should be assessed managed a multidisciplinary approach, involving different professions (psychologists, ear–nose–throat specialists, pulmonologists, allergologists, immunologists, nutritionists, pediatricians, gastroenterologists, psychiatrists (when necessary), others). A approach provides better coping strategies improves control over disease, adherence therapy, quality life. It also has positive influence on family life while at same time making more efficient use dermatology healthcare resources, reducing economic burden both society.
Язык: Английский
Процитировано
29
Journal of Dermatological Treatment, Год журнала: 2023, Номер 34(1)
Опубликована: Фев. 21, 2023
Purpose: The overlap of psoriasis and atopic dermatitis (AD) is rare treating moderate-to-severe cases can be challenging. Conventional immune-suppressive drugs cannot used long-term, no biological are currently approved for both conditions.Method: We report the four patients with overlapping features AD.Result: After being treated several systemic drugs, including gold-standard treatments AD, they received upadacitinib 15 or 30 mg, achieving complete remission. Upadacitinib an inhibitor Janus Kinase 1, AD.Conclusion: To date, very limited data available regarding efficacy in psoriasis. In a phase-3 trial on mg affected by psoriatic arthritis, 52.3% achieved 75% improvement Psoriasis Area Severity Index (PASI75) after one year. Currently, clinical trials evaluating plaque
Язык: Английский
Процитировано
26
American Journal of Clinical Dermatology, Год журнала: 2023, Номер 24(6), С. 953 - 961
Опубликована: Июнь 15, 2023
Janus kinase (JAK) inhibitors, including upadacitinib, have been recently approved for the treatment of moderate-severe atopic dermatitis (AD) and real-world data on upadacitinib effectiveness safety are limited. This interim analysis aimed to assess throughout 48 weeks observation in a adult AD population. prospective study collected patients affected by moderate-to-severe treated with at dosage either 15 mg or 30 daily based physician decision. Upadacitinib was prescribed context national compassionate use programme. In this analysis, within patient comparisons continuous scores different scales (namely Eczema Area Severity Index [EASI], body surface area [BSA], Dermatology Life Quality [DLQI], Patient Oriented Measure [POEM], Numeric Rating Scale [NRS] subtests) were performed. The percentage achieving EASI 75, 90 100 Week 16, 32 also evaluated. One hundred forty-six included analysis. as monotherapy most cases (127/146, 87.0%). initially 118 146 (80.8%) 28/146 (19.2%) patients. A significant improvement clinical signs symptoms detected 16 period. responses achieved 87.6%, 69.1% 44.3% 48, associated sustained reduction mean values all physician-reported (EASI BSA) patient-reported (Itch- Sleep- Pain-NRS, DLQI, POEM) disease severity outcomes, up treatment. Treatment response observed upadacitinib-treated comparable that patients, revealing no statistical difference between two sub-cohorts. Through period, dose escalation 38/146 (26%) cases. Overall, 26 (17.8%) experienced least one adverse event (AE) during total, 29 AEs recorded them evaluated mild moderate, while 4 occurrence AE led drug discontinuation, total 7/146 (4.8%) dropouts. provides strong evidence obtained who had failed respond conventional biological systemic agents, through observation. demonstrated be advantageous terms flexibility shaped needs that, setting, might frequently change.
Язык: Английский
Процитировано
24
Clinical Cosmetic and Investigational Dermatology, Год журнала: 2024, Номер Volume 17, С. 593 - 604
Опубликована: Март 1, 2024
Upadacitinib is a selective Janus kinase inhibitor approved for the treatment of severe atopic dermatitis (AD). This systematic review aims to summarize most recent data in terms effectiveness and safety upadacitinib AD real-world setting. The included comprehensive search databases, including PubMed, Google Scholar Web Science, according Preferred Reporting Items Systematic Reviews Meta-analysis (PRISMA) guidelines. literature initially identified 242 studies. Of these, 214 were excluded after reviewing their titles abstracts. We then conducted full-text 25 studies, which 17 met our inclusion criteria therefore review. analysis studies showed high upadacitinib, both clinical signs subjective symptoms, different patient populations, those resistant other treatments. No new significant concerns have emerged as compared randomized trials.
Язык: Английский
Процитировано
8
Pharmaceuticals, Год журнала: 2024, Номер 17(4), С. 519 - 519
Опубликована: Апрель 18, 2024
Clinical trials and real-world studies have shown the effectiveness of upadacitinib for treating rash pruritus in patients with atopic dermatitis (AD). This study aimed to determine whether early reduction or at week 12 treatment could be maintained later stages. retrospective involved 227 73 moderate-to-severe AD treated 15 30 mg daily, respectively. The eczema area severity index (EASI) scores, peak numerical rating scale (PP-NRS), investigator’s global assessment (IGA) were analyzed. At 12, divided into achievers non-achievers EASI 75, 90, 100, absolute ≤ 2, IGA0/1, PP-NRS4, PP-NRS 1. Achievement rates each endpoint assessed time points (weeks 24, 36, 48) both groups. Week largely their achievements until 48, regardless dosage (15 mg). saw an increasing achievement rate 75 48. initial persisted 48 treatment, suggesting potential benefits requiring prolonged despite not achieving 12.
Язык: Английский
Процитировано
6
Journal of Dermatological Treatment, Год журнала: 2023, Номер 34(1)
Опубликована: Май 29, 2023
Язык: Английский
Процитировано
16
Journal of the European Academy of Dermatology and Venereology, Год журнала: 2023, Номер 38(2)
Опубликована: Сен. 15, 2023
Язык: Английский
Процитировано
16
Immunotherapy, Год журнала: 2023, Номер 15(11), С. 799 - 808
Опубликована: Май 17, 2023
Atopic dermatitis is an inflammatory skin disease, the prevalence of which has increased in last decade. It affects all age groups, with adult involvement being a major focus interest recent years. The unmet needs such as pruritus, sleep quality impairment and eczematous lesions, have undergone therapeutic revolution following commercialization drugs JAK inhibitors. Upadacitinib, selective JAK1 inhibitor, been positioned by both clinical trial results those observed practice fastest most effective drug reducing pruritus Eczema Area Severity Index validated Investigator Global Assessment. Although safety profile may be initially alarming, it advisable to update actual data this regard for proper management. New perspectives upadacitinib nonatopic comorbidities psoriasis alopecia areata are beginning described, learning more about its peculiarities growing.
Язык: Английский
Процитировано
11
Dermatitis, Год журнала: 2024, Номер unknown
Опубликована: Сен. 23, 2024
Upadacitinib, a Janus kinase 1 inhibitor, is an effective medicine for moderate-to-severe atopic dermatitis (AD). Identifying long-term responders to upadacitinib crucial optimal treatment strategies in real-world clinical practice. To identify predictive factors high 15 mg or 30 mg, defined as achievers of investigator's global assessment (IGA) 0/1 with ≥2-point improvement from baseline IGA at week 48.
Язык: Английский
Процитировано
4